In JoVE (1)
Other Publications (1)
Articles by Mayinuer Maitituoheti in JoVE
An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues Christopher Terranova1, Ming Tang1, Elias Orouji1, Mayinuer Maitituoheti1, Ayush Raman1, Samirkumar Amin2, Zhiyi Liu1, Kunal Rai1 1Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, 2The Jackson Laboratory for Genomic Medicine Here, we describe an optimized high-throughput ChIP-sequencing protocol and computational analyses pipeline for the determination of genome-wide chromatin state patterns from frozen tumor tissues and cell lines.
Other articles by Mayinuer Maitituoheti on PubMed
Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression Cell Reports. Apr, 2017 | Pubmed ID: 28445736 The extent and nature of epigenomic changes associated with melanoma progression is poorly understood. Through systematic epigenomic profiling of 35 epigenetic modifications and transcriptomic analysis, we define chromatin state changes associated with melanomagenesis by using a cell phenotypic model of non-tumorigenic and tumorigenic states. Computation of specific chromatin state transitions showed loss of histone acetylations and H3K4me2/3 on regulatory regions proximal to specific cancer-regulatory genes in important melanoma-driving cell signaling pathways. Importantly, such acetylation changes were also observed between benign nevi and malignant melanoma human tissues. Intriguingly, only a small fraction of chromatin state transitions correlated with expected changes in gene expression patterns. Restoration of acetylation levels on deacetylated loci by histone deacetylase (HDAC) inhibitors selectively blocked excessive proliferation in tumorigenic cells and human melanoma cells, suggesting functional roles of observed chromatin state transitions in driving hyperproliferative phenotype. Through these results, we define functionally relevant chromatin states associated with melanoma progression.